The study population comprised patients with histologically confirmed metastatic breast carcinoma that had either progressed or not progressed after first-line chemotherapy for metastatic disease.
Study designs and other criteria for inclusion in the review
Only published Phase II clinical trials of metastatic breast cancer, performed in Western countries, were included in the review.
Sources searched to identify primary studies
Not reported.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Twelve Phase II trials were included in the review.
Methods of combining primary studies
Not relevant as the effectiveness of each drug was evaluated from a single study (i.e. each of the 12 studies evaluated the outcomes of one of the drugs being compared).
The PFLYs for each intervention under study were as follows: 23 (95% confidence interval, CI: 17.3 to 48.5) with cyclophosphamide/methotrexate; 25.5 (95% CI not reported in the study) with intervention 1; intervention 2, outcome not reported in the study; 
Measure of benefits used in the economic analysis
The measures of benefits used were PFLYs and the overall tumour response rate. These measures were derived directly from the studies included in the review.
The results of the sensitivity analyses were reported to be robust to variations in key parameters with few exceptions.
Authors' conclusions
Metronomic cyclophosphamide-methotrexate was significantly cost-effective.
CRD COMMENTARY -Selection of comparators
A justification was given for the comparators used. They represented novel chemotherapy strategies in metastatic breast cancer. You should decide if the comparators represent current practice in your own settings.
Validity of estimate of measure of effectiveness
The authors did not state that a systematic review of the literature had been undertaken to identify all relevant research and minimise biases. The authors reported the entry criteria for inclusion in the review (mainly Phase II trials undertaken in Western countries). For each of the twelve drugs under study, the outcomes of each were derived from a separate study. However, the authors do not appear to have compared any potential differences in the study populations and samples of each study, nor did they assess the validity of the studies included. Therefore, differences in treatment outcomes could be due to differences in study participants (i.e. age, disease severity, deprivation, etc.) rather than treatment effectiveness.
Validity of estimate of measure of benefit
The estimation of benefits was obtained directly from the effectiveness studies. The choice of estimate was not justified. As the authors acknowledged, tumour responses should be interpreted cautiously as an outcome of metastatic breast cancer therapy. A more general measure of health benefit, such as the number of quality-adjusted life-years gained, would facilitate comparisons of the study results with those from different interventions.
Validity of estimate of costs
All the categories of cost relevant to the health care system perspective adopted appear to have been included in the analysis, although the costs of antibacterial chemotherapy associated with the risk of infectious complications might have been omitted from the analysis since the authors mentioned that their incidence was considered to be minor. The costs and resource use were not reported separately (which would hinder reflation exercises in other settings), but the authors did report costs according to resource use category. Resource use was derived from the same studies as those used in the review of effectiveness. As before, for each of the twelve drugs under study, resource use was derived from a separate study. However, the authors do not appear to have compared any potential differences in the study populations and samples of each study. Therefore, differences in resource use could be due to differences in study participants (i.e. age, disease severity, deprivation, etc.) rather than the resource use requirements of each treatment.
The unit costs were derived from published sources. Appropriate one-way sensitivity analyses were undertaken. The authors reported median costs which, although valuable when dealing with skewed data, do not convey the average cost for each patient; this might be important for policy-makers when estimating the potential cost of their decisions. The price year was appropriately reported, which will aid any possible inflation exercises. The authors do not appear to have used discounting, although it is unclear whether it was necessary since the time horizon considered for the cost estimation was not clear.
